Please assess the completion status of the following clinical trial:

Trial Title: Safety of Ramelteon in Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Self-reported sleep latency of 30 minutes or greater on at least 3 nights per week during the last 3 months.~* Body mass index between 18 and 34, inclusive~* Habitual bedtime between 9 pm and 1 am.~Exclusion Criteria~* Performance outside of normal limits on the EquiTest Motor Control Test at the Screening Visit.~* Average score on the EquiTest Sensory Organization Test #5 of less than 40 at the Screening Visit.~* Average score on the EquiTest Sensory Organization Test #6 of less than 40 at the Screening Visit.~* History of sleep apnea, restless leg syndrome, period limb movement syndrome, or other known disorders which affect sleep with the exception of insomnia.~* Current vestibular system disorder or inner ear disease.~* Recent history of clinically significant head injury.~* Significant visual acuity or field abnormalities that are not improved with the use of corrective lenses.~* History of balance disturbance or frequent falling.~* History of seizures, strokes, degenerative neurological disease, fibromyalgia, diabetic neuropathy, thyroid dysfunction, hypotension, clinically significant arthritis or musculoskeletal disorder.~* History of cancer, other than basal cell carcinoma, that has not been in remission for at least five years prior to the first dose of study drug.~* Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable.~* Acute clinically significant illness within two weeks or has been hospitalized within four weeks prior to the Screening Visit.~* History of treatment for a psychiatric disorder (including anxiety, depression, mental retardation, cognitive disorder, bipolar illness and schizophrenia) within the past six months.~* History of drug addiction or drug abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised.~* History of alcohol abuse within the past 12 months.~* Any clinically important abnormal finding, as determined by medical history, physical examination, electrocardiogram or clinical laboratory tests, as determined by the investigator.~* Positive hepatitis panel.~* Positive urine drug screen for drugs known to alter sleep.~* Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.~* Any additional condition that in the Investigator's opinion would:~  * affect sleep-wake function~ * prohibit the subject from completing the study~ * not be in the best interest of the subject.~* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~  * Melatonin and all other drugs or supplements known to affect sleep/wake function~ * Anxiolytics~ * Sedatives~ * Hypnotics~ * Central nervous system active drugs (including herbal)~ * Antidepressants~ * Narcotic analgesics~ * Anticonvulsants~ * Beta blockers~ * Sedating H1 antihistamines~ * St. John's Wort~ * Systemic steroids~ * Kava-kava~ * Respiratory stimulants~ * Ginkgo-biloba~ * Decongestants~ * Over-the-counter and prescription stimulants~ * Antipsychotics~ * Over-the-counter and prescription diet aids~ * Muscle relaxants

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ramelteon 8 mg, zolpidem 10 mg and placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).